GT
GTBP.US GT Biopharma Inc
- Market cap
- USD 7.67M
- P/E
- -
- P/B
- 1.88x
- ROE
- -411.9%
- Dividend yield
- 2.99%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GTBP.US undervalued?
Graham numberThe Graham number of GT Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GT Biopharma Inc fundamental analysis
No fundamental analysis for GT Biopharma Inc yet.
GT Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface o…
Full company profileGT Biopharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GT Biopharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 27.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -1.00K | -2.00K | -7.00K | -4.00K | - | - | - | - | - | - | - |
| Operating Income | -9.37M | -136M | -250M | -11.5M | -6.76M | -57.5M | -21.3M | -13.6M | -14.4M | -12.4M | -14.7M |
| EBITDA | -9.37M | -136M | -250M | -36.5M | -25.0M | -57.5M | -21.0M | 5.98M | -13.2M | -28.2M | -14.4M |
| Net Income | 9.77M | -144M | -259M | -38.6M | -28.3M | -58.0M | -20.9M | -7.60M | -13.2M | -28.4M | -14.7M |
| EPS | 1,628,000 | -3,654 | -2,193 | -285 | -161 | -52 | -16 | -141 | -173 | -129 | -9.47 |
| Balance Sheet | |||||||||||
| Total Assets | 25.0K | 254M | 25.4M | 396K | 5.66M | 32.2M | 16.7M | 14.1M | 4.23M | 8.11M | 5.79M |
| Total Liabilities | 18.9M | 2.68M | 14.0M | 19.7M | 35.1M | 10.3M | 5.00M | 6.63M | 5.90M | 2.32M | 2.22M |
| Shareholders' Equity | -18.8M | 252M | 11.5M | -19.1M | -29.3M | 21.9M | 11.7M | 7.48M | -1.67M | 5.79M | 3.57M |
| Cash & Short-term Investments | 19.0K | 576K | 60.0K | 28.0K | 5.30M | 32.0M | 16.5M | 14.0M | 3.95M | 6.81M | 4.96M |
| Total Debt | 12.4M | 31.0K | 10.8M | 13.4M | 26.3M | 31.0K | 174K | 58.0K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.93M | -5.43M | -10.7M | -3.66M | -7.26M | -15.6M | -15.2M | -8.85M | -12.9M | -12.9M | -13.5M |
| Capital Expenditure | 4.00K | 4.00K | 36.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.93M | -5.43M | -10.7M | -3.66M | -7.26M | -15.6M | -15.2M | -8.85M | -12.9M | -12.9M | -13.5M |
| Ratios | |||||||||||
| ROE | - | -57.2% | -2,246.2% | - | - | -264.8% | -178.0% | -101.6% | - | -490.0% | -411.9% |
| ROA | 39,072.0% | -56.7% | -1,020.5% | -9,759.3% | -499.8% | -180.3% | -124.8% | -53.8% | -311.0% | -349.8% | -254.0% |
| Net Profit Margin | - | -533,970.4% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | 0.00x | 0.94x | - | - | 0.00x | 0.01x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GT Biopharma Inc dividends
- Dividend yield
- 2.99%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 229K | 1.04 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Sep 8, 2026.
Who owns GT Biopharma Inc
- Insiders 10.54%
- Institutions 7.40%
- Public & others 82.06%
- Shares outstanding 2.06M
- Free float 1.55M
Top funds holding GTBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Abante Quant Value FI | 148K | 0.29% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 6.69K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.48K | 0.12% | -0.04% | Sep 2026 |
| Fidelity Total Market Index | 87.00 | 0.00% | -1.14% | Sep 2026 |
| Guggenheim Active Allocation Fund | 6.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding GTBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 376K | 0.73% | -16.70% | Jun 2026 |
| Geode Capital Management, LLC | 267K | 0.52% | -9.40% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 226K | 0.44% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 107K | 0.21% | 0.00% | Jun 2026 |
| Everhart Financial Group, Inc. | 100K | 0.19% | 0.00% | Jun 2026 |
| SRS Capital Advisors Inc | 93.6K | 0.18% | 0.00% | Jun 2026 |
| Opal Wealth Advisors, LLC | 81.8K | 0.16% | 0.00% | Jun 2026 |
| Northern Trust Corp | 75.5K | 0.15% | 0.00% | Jun 2026 |
| Alongside LLC | 64.0K | 0.12% | 0.00% | Jun 2026 |
| Cetera Investment Advisers | 55.9K | 0.11% | 0.00% | Jun 2026 |
| Seacrest Wealth Management, LLC | 50.1K | 0.10% | +0.20% | Jun 2026 |
| PNC Financial Services Group Inc | 40.0K | 0.08% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 38.5K | 0.07% | +83.33% | Jun 2026 |
| LPL Financial Corp | 36.4K | 0.07% | +19.74% | Jun 2026 |
| StoneX Group Inc | 23.3K | 0.05% | +57.62% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 22.6K | 0.04% | +35.99% | Jun 2026 |
| BlueCreek Investment Partners, LLC | 20.8K | 0.04% | 0.00% | Jun 2026 |
| CI Private Wealth LLC | 20.0K | 0.04% | 0.00% | Jun 2026 |
| SAGESPRING WEALTH PARTNERS, LLC | 20.0K | 0.04% | 0.00% | Jun 2026 |
| Private Wealth Management Group LLC | 20.0K | 0.04% | 0.00% | Jun 2026 |
GT Biopharma Inc company profile
- Company name
- GT Biopharma Inc
- Ticker
- GTBP.US
- Exchange
- USA Stocks
- Listed since
- Sep 22, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 315 Montgomery Street, San Francisco, CA, United States, 94104
- Phone
- 415 919 4040
- Website
- gtbiopharma.com
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
GT Biopharma Inc management
2- Mr. Michael Martin Breen L.L.B.President, CEO & Executive Chairman · born 1963
- Mr. Alan Louis Urban CPACFO & Secretary · born 1968